Literature DB >> 22090359

STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma.

Banibrata Sen1, Shaohua Peng, Denise M Woods, Ignacio Wistuba, Diana Bell, Adel K El-Naggar, Stephen Y Lai, Faye M Johnson.   

Abstract

PURPOSE: The inhibition of c-Src results in a striking reduction in cancer cell invasion, but the effect on cell survival is modest. Defining mechanisms that limit apoptosis following c-Src inhibition could result in an ideal therapeutic approach that both inhibits invasion and leads to apoptosis. In this regard, we discovered a novel feedback loop that results in STAT3 reactivation following sustained c-Src inhibition. Here we define the mechanism underlying this feedback loop and examine the effect of inhibiting it in vivo. EXPERIMENTAL
DESIGN: We measured levels and activity of pathway components using PCR, Western blotting, and kinase assays following their manipulation using both molecular and pharmacologic approaches. We used a heterotransplant animal model in which human oral squamous cancer is maintained exclusively in vivo.
RESULTS: Following c-Src inhibition, STAT5 is durably inhibited. The inhibition of STAT5A, but not STAT5B, subsequently reduces the expression of suppressors of cytokine signaling 2 (SOCS2). SOCS2 inhibits Janus kinase 2 (Jak2) activity and Jak2-STAT3 binding. SOCS2 expression is necessary for STAT3 inhibition by c-Src inhibitors. Overexpression of SOCS2 is adequate to prevent STAT3 reactivation and to enhance the cytotoxic effects of c-Src inhibition. Likewise, the combination of Jak and c-Src inhibitors led to significantly more apoptosis than either agent alone in vivo.
CONCLUSIONS: To our knowledge, ours is the first study that fully defines the mechanism underlying this feedback loop, in which sustained c-Src inhibition leads to diminished SOCS2 expression via sustained inhibition of STAT5A, allowing activation of Jak2 and STAT3, Jak2-STAT3 binding, and survival signals.
© 2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22090359      PMCID: PMC3251692          DOI: 10.1158/1078-0432.CCR-11-1889

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  51 in total

1.  Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.

Authors:  Tin Lap Lee; Jason Yeh; Carter Van Waes; Zhong Chen
Journal:  Mol Cancer Ther       Date:  2006-01       Impact factor: 6.261

Review 2.  Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.

Authors:  Stephen Y Lai; Faye M Johnson
Journal:  Drug Resist Updat       Date:  2010-05-14       Impact factor: 18.500

3.  Stat5a inhibits IL-12-induced Th1 cell differentiation through the induction of suppressor of cytokine signaling 3 expression.

Authors:  Hiroaki Takatori; Hiroshi Nakajima; Shin-ichiro Kagami; Koichi Hirose; Akira Suto; Kotaro Suzuki; Masato Kubo; Akihiko Yoshimura; Yasushi Saito; Itsuo Iwamoto
Journal:  J Immunol       Date:  2005-04-01       Impact factor: 5.422

4.  ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases.

Authors:  M A Olayioye; I Beuvink; K Horsch; J M Daly; N E Hynes
Journal:  J Biol Chem       Date:  1999-06-11       Impact factor: 5.157

5.  Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor.

Authors:  D W Leaman; S Pisharody; T W Flickinger; M A Commane; J Schlessinger; I M Kerr; D E Levy; G R Stark
Journal:  Mol Cell Biol       Date:  1996-01       Impact factor: 4.272

6.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.

Authors:  R Garcia; T L Bowman; G Niu; H Yu; S Minton; C A Muro-Cacho; C E Cox; R Falcone; R Fairclough; S Parsons; A Laudano; A Gazit; A Levitzki; A Kraker; R Jove
Journal:  Oncogene       Date:  2001-05-03       Impact factor: 9.867

Review 7.  SOCS regulation of the JAK/STAT signalling pathway.

Authors:  Ben A Croker; Hiu Kiu; Sandra E Nicholson
Journal:  Semin Cell Dev Biol       Date:  2008-07-30       Impact factor: 7.727

8.  Inhibition of transcription factor STAT5b suppresses proliferation, induces G1 cell cycle arrest and reduces tumor cell invasion in human glioblastoma multiforme cells.

Authors:  Qin-Chuan Liang; Hua Xiong; Zhen-Wei Zhao; Dong Jia; Wei-Xin Li; Huai-Zhou Qin; Jian-Ping Deng; Li Gao; Hua Zhang; Guo-Dong Gao
Journal:  Cancer Lett       Date:  2008-09-14       Impact factor: 8.679

9.  Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Authors:  Iduna Fichtner; Jana Rolff; Richie Soong; Jens Hoffmann; Stefanie Hammer; Anette Sommer; Michael Becker; Johannes Merk
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

10.  Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.

Authors:  Anne S Tsao; Dandan He; Babita Saigal; Suyu Liu; J Jack Lee; Srinivasa Bakkannagari; Nelson G Ordonez; Waun Ki Hong; Ignacio Wistuba; Faye M Johnson
Journal:  Mol Cancer Ther       Date:  2007-07       Impact factor: 6.261

View more
  24 in total

Review 1.  Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy.

Authors:  Jeremy S Logue; Deborah K Morrison
Journal:  Genes Dev       Date:  2012-04-01       Impact factor: 11.361

Review 2.  The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs.

Authors:  Ulrich H Weidle; Alexandra Epp; Fabian Birzele; Ulrich Brinkmann
Journal:  Cancer Genomics Proteomics       Date:  2019 Jan-Feb       Impact factor: 4.069

3.  Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling.

Authors:  Julhash U Kazi; Lars Rönnstrand
Journal:  Mol Oncol       Date:  2013-03-19       Impact factor: 6.603

4.  Dasatinib Inhibits DNA Repair after Radiotherapy Specifically in pSFK-Expressing Tumor Areas in Head and Neck Xenograft Tumors.

Authors:  Hanneke Stegeman; Paul N Span; Paul F J W Rijken; Simone C Cockx; Deric L Wheeler; Mari Iida; Albert J van der Kogel; Johannes H A M Kaanders; Johan Bussink
Journal:  Transl Oncol       Date:  2013-08-01       Impact factor: 4.243

5.  Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Authors:  Russell J Schilder; William E Brady; Heather A Lankes; James V Fiorica; Mark S Shahin; Xun C Zhou; Robert S Mannel; Harsh B Pathak; Wei Hu; R Katherine Alpaugh; Anil K Sood; Andrew K Godwin
Journal:  Gynecol Oncol       Date:  2012-06-16       Impact factor: 5.482

6.  Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.

Authors:  Ming Zhang; Ratnakar Singh; Shaohua Peng; Tuhina Mazumdar; Vaishnavi Sambandam; Li Shen; Pan Tong; Lerong Li; Nene N Kalu; Curtis R Pickering; Mitchell Frederick; Jeffrey N Myers; Jing Wang; Faye M Johnson
Journal:  Cancer Lett       Date:  2017-01-23       Impact factor: 8.679

7.  FAK and Src expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.

Authors:  Stamatios Theocharis; Jerzy Klijanienko; Constantinos Giaginis; Paraskevi Alexandrou; Efstratios Patsouris; Xavier Sastre-Garau
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-10       Impact factor: 4.553

8.  Turn down genes for WAT? Activation of anti-apoptosis pathways protects white adipose tissue in metabolically depressed thirteen-lined ground squirrels.

Authors:  Samantha M Logan; Bryan E Luu; Kenneth B Storey
Journal:  Mol Cell Biochem       Date:  2016-03-31       Impact factor: 3.396

9.  Expression of SOCSs in human prostate cancer and their association in prognosis.

Authors:  Jian-guo Zhu; Qi-shan Dai; Zhao-dong Han; Hui-chan He; Ru-jun Mo; Guo Chen; Yan-fei Chen; Yong-ding Wu; Sheng-bang Yang; Fu-neng Jiang; Wei-hong Chen; Zhao-lin Sun; Wei-de Zhong
Journal:  Mol Cell Biochem       Date:  2013-05-11       Impact factor: 3.396

10.  A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.

Authors:  Tuhina Mazumdar; Lauren A Byers; Patrick Kwok Shing Ng; Gordon B Mills; Shaohua Peng; Lixia Diao; You-Hong Fan; Katherine Stemke-Hale; John V Heymach; Jeffrey N Myers; Bonnie S Glisson; Faye M Johnson
Journal:  Mol Cancer Ther       Date:  2014-09-05       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.